Company news
Allergy Therapeutics Plc (LSE:AGY) news
Allergy Therapeutics Plc news releases on 6ix. Latest, Jul 29, 2026: Trading update for the year ended 30 June 2026
Press releases & updates
Trading update for the year ended 30 June 2026
July 29, 2026
Appointment of Executive Chairman
July 28, 2026
Vesting of Options under Long-Term Incentive Plan
June 30, 2026
Long Term Incentive Awards
June 15, 2026
Allergy Therapeutics to present at EAACI 2026
June 12, 2026
Interim Results for six months ended 31 Dec 2025
March 31, 2026
PDMR Dealings & Shareholding Update
March 12, 2026
Positive Biomarker Results from PROTECT Trial
March 4, 2026
Allergy Therapeutics presents progress at AAAAI
February 26, 2026
Update on funding and total voting rights
February 23, 2026
Allergy Therapeutics : Results of Annual General Meeting
February 2, 2026
Chief Strategy Officer and Board appointments
January 30, 2026
Result of Annual General Meeting
January 29, 2026
Grant of Options under Long Term Incentive Scheme
January 28, 2026
Half Year Trading Update
January 19, 2026
Notice of 2025 Annual General Meeting
January 6, 2026
Results of General Meeting
December 29, 2025
Grassmuno® marketing authorisation in Germany
December 16, 2025
Authority for allotment of New Shares
December 12, 2025
Prelim Results and publication of Annual Report
December 11, 2025
Primary Safety Endpoint Met in PROTECT trial
December 9, 2025
Company to Evaluate Dual Listing on HKEX
November 6, 2025
G308 Phase III Year 2 Patient Screening Starts
October 30, 2025
Warrant Exercise and Paydown of Debt
October 29, 2025
Further progress in Phase I/IIa PROTECT trial
October 16, 2025
Grass MATA MPL Publications in Allergy Journal
July 31, 2025
Trading update for the year ended 30 June 2025
July 21, 2025
PDMR Dealings
July 11, 2025
Allergy Therapeutics presents findings at EAACI
June 13, 2025
EAACI Early Career Research Award
June 10, 2025
Interim Results for six months ended 31 Dec 2024
March 31, 2025
Advancement to final phase of PROTECT trial
March 27, 2025
New Executive Long Term Incentive Awards
March 3, 2025
Presentations at 2025 AAAAI / WAO Joint Congress
February 27, 2025
Grass MATA MPL Phase III data published in Allergy
February 17, 2025
Grant of Options
February 14, 2025
Half Year Trading update
January 28, 2025
PDMR Dealing and Total Voting Rights
January 22, 2025
Director/PDMR Shareholding
January 15, 2025
Exercise of Options and Total Voting Rights
December 19, 2024
Block Listing Interim Review
December 17, 2024
Positive Interim Data from PROTECT Trial
December 4, 2024
First Patient Dosed in G308 Paediatric Trial
November 27, 2024
Submission of MAA for Grass MATA MPL
November 25, 2024
Allergy Therapeutics plc - Notice of 2024 Annual General Meeting
November 22, 2024
Notice of 2024 Annual General Meeting
November 21, 2024
Audited Preliminary Results 2024
November 6, 2024
Commencement of Phase III Paediatric Trial
October 21, 2024
Update on funding
October 16, 2024
Update on funding and preliminary results
October 1, 2024